Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis
- *Corresponding Author:
- Moses Rodriguez
Department of Neurology
Guggenheim 4-42B, 200 1st Street SW
Mayo Clinic, Rochester
MN 55901, USA
E-mail: [email protected]
Received date: May 23, 2016; Accepted date: June 17, 2016; Published date: June 23, 2016
Citation: Dasari H, Wootla B, Warrington AE, Rodriguez M (2016) Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis . Int J Phys Med Rehabil 4: 348. doi: 10.4172/2329-9096.1000348
Copyright: © 2016 Dasari H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted `use, distribution, and reproduction in any medium, provided the original author and source are credited.
We provide an overview of rehabilitation in neurological diseases. A large amount of literature available on neurorehabilitation is based from the rehabilitative work on stroke and spinal cord injuries. After a brief description of rehabilitation, the potential application of neurorehabilitation in neurodegenerative diseases specifically multiple sclerosis (MS) is summarized. Since MS causes a wide variety of symptoms, the rehabilitation in MS patients may benefit from an interdisciplinary approach that encloses physiotherapy, cognitive rehabilitation, psychological therapy, occupational therapy, and other methods to improve fatigue. Neurorehabilitation helps patients to reach and maintain their optimal physical, psychological and intellectual, levels but it does not reverse long-term disabilities that arise from neurological disorders. This calls for the need of better neuroregenerative and neuroprotective treatment strategies in addition to neurorehabilitation. We discuss neuroprotective drugs aimed at preventing axonal, neuronal, myelin and oligodendrocyte damage and cell death that are approved and others that are currently in clinical trials, with an emphasis on human derived natural antibodies with remyleination potential. Our investigative group developed recombinant natural human IgM antibodies against oligodendrocytes and neurons with a potential for CNS repair and remyleination. One such recombinant antibody, rHIgM22 completed a phase 1 clinical trial with no toxicity and with an objective of promoting remyleination in multiple sclerosis. Inclusion of these drugs as a multifaceted approach may further enhance the efficacy of neurorehabilitation in neuroinflammatory and neurodegenerative disorders.